In a recent filing with the US Securities and Exchange Commission, Alex Denner‘s Sarissa Capital Management has reported entering into an amendment to the nomination agreement with Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR). Under the terms of the amendment, the standstill provisions were terminated and Sarissa will not submit a director nomination notice or business proposal under Aegerion’s bylaws for the company’s 2016 meeting of shareholders.
Sarissa owns 2.58 million shares of Aegerion Pharmaceuticals, according to its last 13F filing. Overall, 15 funds from our database reported long positions in the company as of the end of December, down by one over the quarter. The largest position among the investors we track, is held by Matt Sirovich and Jeremy Mindich’s Scopia Capital, which disclosed a $57.6 million stake in its last 13F filing, followed by Kevin Kotler’s Broadfin Capital with a $35.5 million holding. On the other hand, Conan Laughlin’s North Tide Capital unloaded its entire holding in Aegerion that was worth $12.5 million.
You can access the original SEC filing by clicking here.
Follow Alex Denner's Sarissa Capital Management
Page 1 of 3 – SEC Filing
|
CUSIP No. 00767E102
|
Page 1 of 3 Pages
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
Aegerion Pharmaceuticals, Inc.
|
|
(Name of Issuer)
|
|
Common Stock, $0.001 par value
|
|
(Title of Class of Securities)
|
|
00767E102
|
|
(CUSIP Number)
|
|
Mark DiPaolo
General Counsel
Sarissa Capital Management LP
660 Steamboat Road
Greenwich, CT 06830
203-302-2330
With a copy to:
Russell Leaf
Willkie Farr & Gallagher LLP
787 Seventh Avenue
New York, New York 10019
212-728-8000
|
|
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications) |
|
March 21, 2016
|
|
(Date of Event which Requires Filing of this Statement)
|